Kornimate/medical-research-clean huggingface dataset:
efficacy of the adipose graft transposition procedure (agtp) in patients with a myocardial scar: the agtp ii trial

Conditions: Myocardial Infarction

Summary: the purpose of this trial is to evaluate the efficacy of a pericardial adipose graft transposition (adipose graft trasposition procedure, agtp) for the improvement of cardiac function in patients with a chronic myocardial infarction. preclinical studies in the porcine model of myocardial infarction have shown that the agtp reduces infarct area and improves cardiac function. a first-in-man clinical (nct01473433) trial showed that the agtp is safe in patients.


Eligibility criteria:
inclusion criteria: * \> 18 years of age, capable of giving informed consent. * q wave in the ecg * myocardial infarct \>=50% transmularity by nmr non revascularizable (for transmurality or bad vessel). * candidate to bypass for other myocardial areas exclusion criteria: * severe non cardiac co-morbidity with a reduction of life expectancy of less than 1 year * severe valvular disease candidate for surgical restoration * candidate to ventricular remodeling * contraindication for nmr * severe renal or hepatic failure * abnoraml laboratory tests (no explanation at inclusion) * previous cardiac intervention * pregnant or breast feeding women

Keywords: myocardial infarction cardiac regeneration cardiac surgery
passive immunity trial for our nation to treat covid-19 in hospitalized adults

Conditions: COVID-19; Coronavirus; SARS-CoV-2

Summary: the purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat covid-19 in hospitalized adults in a randomized, placebo-controlled setting. the effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the covid-19 7-point ordinal clinical progression outcomes scale at day 15, among adults with covid-19 requiring hospitalization.

after being informed about the study and potential risks, participants confirmed to meet all eligibility criteria who have provided informed consent will be randomized 1:1 to convalescent plasma versus placebo. transfusion of convalescent plasma or placebo will be administered by clinical or research personnel while the patient is hospitalized on study day 1. on study days 1-7, participants will be monitored for adverse reactions to the transfusion. research personnel will also assess patients at day 14 and day 28; these assessments will be completed by phone if the participant has been discharged from the hospital.

Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years 2. currently hospitalized or in an emergency department with anticipated hospitalization 3. symptoms of acute respiratory infection, defined as one or more of the following: 1. cough 2. chills, or a fever (greater than 37.5° c or 99.5° f) 3. shortness of breath, operationalized as a patient having any of the following: i. subjective shortness of breath reported by a patient or surrogate. ii. tachypnea with respiratory rate of greater than 22 breaths per minute iii. hypoxemia, defined as spo2 less than 92% on room air, new receipt of supplemental oxygen to maintain spo2 greater than or equal to 92%, or increased supplemental oxygen to maintain spo2 greater than or equal to 92% for a patient on chronic oxygen therapy 4. laboratory-confirmed sars-cov-2 infection within the past 14 days exclusion criteria: 1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

Keywords: covid-19 drug treatment convalescent plasma
the effects of functional power training on frail and pre-frail community - dwelling older adults in singapore

Conditions: Frailty; Muscle Weakness

Summary: to investigate the efficacy of a 12-week functional power training (fpt) program in pre-frail and frail community-dwelling older adults in singapore for the management of physical frailty. the proposed study will provide information on the benefits of fpt on physical performances of older adults and help to shape future exercise recommendations to slow or reverse the onset and severity of physical frailty.


Eligibility criteria:
inclusion criteria: * aged 55 years and above * low muscle strength - handgrip strength less than 26kg for men and 18kg for women * ambulate without human assistance * able to understand basic instructions exclusion criteria: * currently enrolled in another study * acute musculoskeletal injury * unable to participate in the full duration of the study * unwilling to participate if not assigned to the intervention group * deemed not suitable to participate in exercise by a medical doctor
novel pet/ct agents and mrs/mri in prostate ca and high risk prostate cancer: an inter-spore collaboration

Conditions: Prostate Cancer

Summary: prostate cancer imaging using traditional anatomic modalities including ct, mr, and ultrasound is limited. improvement in current imaging modalities or development of new ones should be a priority in prostate cancer research. optimal treatment varies considerably for patients with different staging characterizations and new imaging methods that more accurately stage patients could lead to more appropriate treatment. the objective of this study is to obtain preliminary, comparative data on new, promising imaging methods for prostate cancer. pet/ct imaging using 11c-choline,11c-acetate, and y86 or 18f-adenosylcobalamin and mri spectroscopy (mrs) of prostate cancer will be compared. direct comparison of these imaging methods has never been done and mayo clinic and johns hopkins are uniquely able to conduct such a trial as an inter-spore collaboration.


Eligibility criteria:
inclusion criteria: * males 18 years of age or older * patients who have completed staging ct and/or bone scan as part of their routine workup * patients with bulky metastatic prostate cancer who have 5 or more lesions suspicious for distant metastases as determined by routine ct and/or bone scans that are untreated by radiation exclusion criteria: * patients who are less than 6 weeks post operative for greenfield filter placement * patients with metallic surgical implants including pacemaker implants, cochlear implants, dentures held in place by magnets imbedded in the gums and aneurysm clips except those inserted at mayo and only those inserted after october of 1994 and /or metal fragments in the body including metal fragments in the eyes
supporting treatment adherence for resilience and thriving (start)

Conditions: Adherence, Medication; HIV-1-infection; Stimulant Use

Summary: this phase ii randomized controlled trial is testing the efficacy of a cell phone application called start for helping men who use stimulants like methamphetamine to get the most out of their hiv treatment.


Eligibility criteria:
1. assigned male at birth; 2. identifies as male; 3. age 18 or older; 4. reads and speaks english; 5. continental us residency; 6. reports ever having had anal sex with a man; 7. self-reported hiv diagnosis for 3 or more months and currently taking anti-retroviral therapy (art) 8. reports a detectable viral load during past year or no viral load test in the past 10+ months or reports \< 90% adherence to art; 9. screens positive for a moderate or severe stimulant use disorder in the past 3 months with an abbreviated version of the national institute on drug abuse (nida)-modified alcohol, smoking and substance. involvement screening test (assist); 10. has an iphone or android smartphone; 11. is willing to participate in an mhealth intervention exclusion criteria: 1. hiv-negative or never tested for hiv; 2. hiv-positive men without a current art prescription; 3. does not return a viable dbs specimen at baseline for viral load testing 4. not a sexual minority man
efficacy of combination of midodrine with propranolol in preventing first bleed in decompensated cirrhotics with severe ascites.

Conditions: Decompensated Cirrhosis; Severe Ascites

Summary: study population: decompensated cirrhotics requiring primary prophylaxis with asciteswho are admitted to and attending the opd at ilbs. study design : a randomized controlled trial study period : august 2019 to december 2020 (1.5 years) intervention : treatment naïve patients will be given propranolol and dose will be titrated every 2ndday to attain a target heart rate of 55. one group patients will be given maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.the patients who bleed will undergo evl session. to the other group midodine will be added to propranolol.it will be started at 2.5mg tds and will be uptitrated every 2nd day to a max of 10mg tds to attain a map of atleast 70mm hg and then uptitate the beta blocker simulataneously to attain the target heart rate. the patients who bleed will undergo evl session. monitoring and assessment : the patient will be monitored every day. the patient will undergo physical examination, complete blood counts, at baseline, lft, kft, at every 2nd day and day 7 from the start of therapy. adverse effects : bradycardia and hypotension due to beta blockers stopping rule : severe hyponatraemia (\ 1.5) identifies more vulnerable patients among those with decompensated cirrhosis, in whom a dose reduction or temporal discontinuation of nsbb treatment will be considered.


Eligibility criteria:
inclusion criteria: decompensated child c cirrhotics with grade ii-iii requiring primary prophylaxis exclusion criteria: 1. spontaneous bacterial peritonitis 2. hepatic encephalopathy 3. acute renal failure (s.cr\>1.5) 4. hepatorenal syndrome 5. hypertension 6. coronary artery disease ; h/o arrhythmias, heart block 7. urinary retention 8. pheochromocytoma/thyrotoxicosis 9. coronary obstructive pulmonary disease 10. hepatocellular carcinoma 11. pregnancy 12. portal vein thrombosis
a trial investigating nn1218 in subjects with type 1 and type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe and in the united states of america (usa). the aim of this trial is to investigate the absorption and effect in the body of nn1218 in subjects with type 1 and type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus for more than 12 months * treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (csii) for 12 months or longer for subjects with type 1 diabetes and for 3 months or longer for subjects with type 2 diabetes * body mass index (bmi) between 18.0-32.0 kg/m2 (both inclusive) exclusion criteria: * surgery or trauma with significant blood loss (more than 500 ml) within the last 3 months prior to trial start * smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) * not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
promoting asthma wellness in rural communities

Conditions: Asthma

Summary: this is a research study that compares the effectiveness of a web-based program (known as puff city) and another web-based program (of internet sites such as the american lung association, american academy of asthma, allergy, and immunology, etc) that targets five key asthma management issues among rural youth: 1. improving adherence to asthma controller medication use; 2. improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms; 3. improving inhaler technique; 4. smoking reduction or cessation in those who are smokers; and 5. avoidance of second-hand smoke exposure.

a randomized control trial across three southeastern rural high schools comparing a web-based tailored intervention (known as puff city) to web-based traditional control education sites.

Eligibility criteria:
inclusion criteria: * aa ethnicity * in 9th - 11th grade of selected rural schools * have an asthma diagnosis and/or asthma-like symptoms by screening eligible on the lung health survey * have access to a telephone or mobile phone * being the parent of a student meeting the above criteria with whom the student resides the majority of the time. exclusion criteria: * not meeting the above criteria.

Keywords: asthma smoking teens
jab-3312 based combination therapy in adult patients with advanced solid tumors

Conditions: Solid Tumor; NSCLC

Summary: to evaluate the safety and tolerability of jab-3312 administered in investigational regimens in adult participants with advanced solid tumors.

to assess the safety and tolerability and determine the recommended phase 2 dose (rp2d) of jab-3312 in combination with pd1 inhibitor or mek inhibitor in patients with advanced solid tumors.

Eligibility criteria:
inclusion criteria: * must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. some cohorts must meet specific expression or gene mutation where indicated * sufficient organ function * participants must have at least 1 measurable lesion as defined by recist v1.1 * must be able to provide an archived tumor sample * ecog performance status score of 0 or 1. exclusion criteria: * history of cancer that is histologically distinct from the cancers under study * active or untreated central nervous system (cns) metastases * history of pneumonitis or interstitial lung disease (ild) * has active hepatitis b, hepatitis c infection, hiv * any severe and/or uncontrolled medical conditions * lvef ≤50% * qtcf \>470 msec

Keywords: kras g12c, egfr
do patients with skin psoriasis have sub-clinical features of active psoriatic arthritis on musculoskeletal ultrasound?

Conditions: Psoriatic Arthritis

Summary: psoriatic arthritis is an inflammatory condition that typically affects joints and soft tissues such as tendons. poorly controlled or untreated psoriatic arthritis can lead to joint damage, disability and poor physical and mental wellbeing. evidence suggests that early diagnosis and treatment of psoriatic arthritis can minimise adverse health outcomes. musculoskeletal ultrasound has become an extremely useful tool in aiding rheumatologists to diagnose inflammatory joint conditions particularly at an early stage in the course of a disease. psoriatic arthritis is known to affect up to 30% of patients with skin psoriasis. therefore, national dermatology guidelines advise that patients with skin psoriasis should be asked about any joint symptoms at least every year. this study investigates whether skin psoriasis patients who are not on biologic treatment are indeed being asked about any joint symptoms and we subsequently invite patients for a musculoskeletal ultrasound scan to see if they have features of early psoriatic arthritis on ultrasound. those who do are then invited for a thorough rheumatology clinical assessment.


Eligibility criteria:
inclusion criteria: * diagnosis of psoriasis by a dermatologist * aged 18 or more * reasonable fluency of spoken english exclusion criteria: * existing diagnosis of psoriatic arthritis * currently on biologics for treatment of their skin psoriasis (as this would potentially treat and thereby diminish joint symptoms associated with psa) * aged \<18years old (the study focusses on an adult population) * currently in prison (would be unable to attend the study ultrasound scan) * unable to give written consent for a musculoskeletal ultrasound e.g. advanced dementia, learning difficulties (may be unable to appreciate the reason for the study and may be unable to tolerate sitting relatively still for an ultrasound scan for 60 minutes)
physiotherapy in mutated covid-19 patients

Conditions: COVID-19 Pandemic

Summary: the prospective study was conducted at a single location within the covid-19 department of a city hospital. the study included covid-19 patients who were hospitalized in the covid-19 service and consulted for physiotherapy, were between the ages of 18 and 65, and had the capacity and inclination to participate in one daily physiotherapy session five days per week.

a hospital's covid-19 service recruited 32 participants for the study. patients were divided into two groups: covid-19 (n=16; age = 53.81 9.48) and mutation (n=16; age = 55.25 10.12). both groups underwent physiotherapy consisting of mobilization, normal range of motion, and a respiratory exercise program (covid-19 group: 9.945.85 days; mutation group: 7.632.83 days). every patient participated in a once-daily physiotherapy program. the patients' muscle strength, mobility, daily activities, exercise capacity, and perception of fatigue were assessed. to compare groups, the mixed repeated measures anova model was used.

Eligibility criteria:
inclusion criteria: patients with covid-19 who were hospitalized in the covid-19 service patients were consulted for physiotherapy patients with the capacity and willingness to participate in one daily physiotherapy session five days a week exclusion criteria: * patients who had an exercise contraindication, were uncooperative, had multi-organ failure, had an acute infection, or were peg-fed were excluded.
m-rose combined with mngs in severe hospital-acquired pneumonia

Conditions: Pneumonia

Summary: the purpose of this study is to determine the value of m-rose（microbiological rapid on-site evaluation）in severe hospital-acquired pneumonia.

severe hospital acquired pneumonia (shap) is the critical risk factor leading to the death of nosocomial infection patients. rapid identification of pathogens, guidance of individualized treatment and rational application of antibiotics can not only improve the administration of antibiotics, but also reduce the production of multi drug resistant bacteria. metagenomic second-generation sequencing (mngs) is an important tool to quickly identify the pathogen in icu. however, due to the low qualified rate of lower respiratory tract specimens in patients with shap, easily polluted, and the difficulty to determine whether microorganisms are infectious, colonizated or polluted, the value of mngs was limited in the etiological diagnosis of shap. the bedside m-rose system established by our research team can determine whether the lower respiratory tract specimen is qualified, whether infection exists and the pathogen of infection within half an hour. based on the previous work, this project plans to conduct a prospective multicenter, single blind, randomized controlled study under the guidance of m-rose and mngs in the individualized anti-infection strategy of shap, to reduce the mortality of patients with shap; combined with the third-generation sequencing, the standard analysis framework for the traceability and prevention and control of drug-resistant bacteria was established to clarify the transmission route of drug-resistant bacteria, so as to provide a new solution for the prevention and control of clinical multidrug-resistant bacteria.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of severe hospital-acquired pneumonia * must have undergone bronchoalveolar lavage exclusion criteria: * balf samples were not sent for mngs examination * age \< 18 years old * the hospitalization days ≤ 3 * the clinical data are incomplete * mechanical ventilation time \> 60 days

Keywords: m-rose mngs severe hospital-acquired pneumonia treatment
xinju xiaogao prescription study on overweight

Conditions: Overweight

Summary: xinju xiaogao prescription and 10% of it in the treatment of adiposity (stagnation of qi causing phlegm retention)clinical study

charged by the three research centers in line with traditional chinese medicine stagnation of qi causing phlegm retention 120 cases have diabetes were randomly divided into chinese herbal compound xinju xiaogao prescription group and 10% of the prescription group.the treatment groups were compared 24-week step-down and regulation of body weight,waistline, blood lipids, blood sugar effect.

Eligibility criteria:
inclusion criteria: * aged 18-60 years old * bmi≥28kg/m2，but\<40kg/m2 * waistline≥85cm（male）,≥80cm（female） * pathoglycemia must fulfill one of those four condition: * igt,7.8≤2hpg≤11.0mmol/, * diabetics take medicine used to treat type 2 diabetes more than 3 month,and 5.6≤fbg≤12.2,and weight change under 4kg. * stagnation of qi causing phlegm retention * to sign informed consent. exclusion criteria: * after 3-6 months simply controlling their diet and more exercise treatment, body weight weight loss ≥ 5%. * tg\>4.5mmol/l. * suffering from congenital heart disease, rheumatic heart disease, kidney disease, serious active liver disease, peptic ulcer disease or malabsorption syndrome. * there is a history of pancreatitis or endocrine diseases other than diabetes, diabetes treated with insulin. * not suffered myocardial infarction in past 3 months or unstable angina were confirmed. * had been diagnosed as "post-surgical adhesions" . * there is a history of appetite or abuse of laxatives * diastolic blood pressure,uncontrolled or controlled, three times greater than 105mmhg . * pregnancy, prepare to pregnant or lactating women prepare. * allergies to chinese medicine , allergic. * recurrent gallstone or a history of kidney stones. * mentally ill. * cancer patients. * a history of gastrointestinal surgery to lose weight. * receiving other clinical studies nearly 3 months. * alcohol and / or psychoactive substances, drug abusers and addicts. * taking other weight-reducing aid close within one month

Keywords: adiposity
ttvr strong under coverage with evidence development (ced) study

Conditions: Tricuspid Regurgitation

Summary: this coverage with evidence development (ced) study measures the long-term health outcomes of patients with severe, symptomatic tricuspid regurgitation who received a transcatheter tricuspid valve replacement procedure using the evoque system.

this is a retrospective, non-randomized cohort study measuring 2-year effectiveness of the evoque transcatheter tricuspid valve replacement (ttvr) system in the real-world. this study will retrospectively evaluate evoque treated patients in the sts/acc tvt registry who have at least severe tricuspid regurgitation and can be deterministically linked with medicare data. this group will be compared to medicare eligible and evoque eligible patients evaluated in a standard of care setting from a commercial claims database linked with electronic health records. we will evaluate the primary outcome measure in various subgroups. there will be continued access enrollment after the primary completion date.

Eligibility criteria:
inclusion criteria: medicare eligible patients who have received an evoque device or are evoque eligible and have at least severe tricuspid regurgitation exclusion criteria: commercially insured patients who have received an evoque device or are evoque eligible or medicare eligible patients with less than severe tricuspid regurgitation

Keywords: evoque coverage with evidence development ced tvt registry